Taipei – One year into the Regenerative Medicine Act, Taiwan’s biotech sector is at a pivotal moment for transformation. The Regenerative Medicine Clinical Trial Education Training Course (August 2-3), hosted by the Taiwan Precision Medicine Society (TPMS) and organized by Gene & Stem Biomedical Company (GSBC), concluded successfully at the National Taiwan University Hospital International Conference Center. Thermo Fisher Scientific’s PPD™ clinical research business—a leading global contract research organization (CRO)—was invited to co-conduct the training. Bringing together experts from the U.S., Taiwan, and Thailand, alongside over 100 participants, the program served as a platform for industry insights exchange and helped expand Taiwan’s biotech influence on the global stage.

Regenerative Medicine’s New Milestone: GSBC Leads the Way to Internationalization

The Regenerative Medicine Act, rolled out in June 2024, has thrust Taiwan into the spotlight of Asia’s biotech scene. GSBC, in view of the global cell and gene therapy trends, collaborated with the global, high-calibre team from U.S.-headquartered Thermo Fisher Scientific’s PPD clinical research business to conduct the professional training program for regenerative medicine clinical trials. This helps Taiwan’s clinical researchers “catch up” on international standards, covering key practices like CRO interfaces, risk management, contracts, and trial launches, linking Taiwan to the global norms.

Moving Global: Institutional Readiness and Talent Development Are Essential

“We don’t just train professionals; we want to make every promising company visible to the world,” said GSBC General Manager and CEO Chang Yi-Wen. As the main organizer of this international training event, GSBC handled course coordination, international alignment, and local regulatory integration, while also playing a “consultant-like role” in driving institutional implementation. Over 100 medical professionals completed the program and earned the training certificate, becoming globally competitive talents and pushing Taiwan’s biotech to new heights.

Beyond Technology: GSBC as the Translator and Bridge for Systems

General Manager and CEO Chang Yi-Wen noted that over the years, they’ve built up experience in regenerative medicine clinical strategy development, hoping to offer the industry full support from front-end design and planning to back-end clinical execution. This time, through collaboration with the team from Thermo Fisher Scientific’s PPD Cell Therapy Center of Excellence, they introduced international standards, expecting to help more medical institutions secure global clinical validation in the future, allowing Taiwan’s trials to truly earn trust from international pharmaceutical companies and investors.

Institutional Rollout and Clinical Practice Must Advance Together. In the future, GSBC will continue partnering with medical societies, hospitals, and industry allies to jointly create a Taiwan model with institutional integrity and regional connectivity, promoting Asian clinical trial cooperation development. Becoming Taiwan’s first gene and cell therapy (CGT) company to step out of Asia and connect to the world as a pusher, creating a new paradigm for Taiwan to advance toward international clinical cooperation.